Active Filter(s):
Details:
The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Lead Product(s): Erythropoietin EPO
Therapeutic Area: Hematology Product Name: rHuEPO
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Blau Farmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 25, 2022